Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies

This publication has 41 references indexed in Scilit:

• C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis
  The Lancet, 2009
• Major Lipids, Apolipoproteins, and Risk of Vascular Disease
  JAMA, 2009
• Genetic variants and haplotypes of lipoprotein associated phospholipase A2 and their influence on cardiovascular disease (The Ludwigshafen Risk and Cardiovascular Health Study)
  Journal of Thrombosis and Haemostasis, 2009
• Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: the Beijing atherosclerosis study
  Human Genetics, 2008
• Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development
  Nature Medicine, 2008
• Consensus Panel Recommendation for Incorporating Lipoprotein-Associated Phospholipase A2 Testing into Cardiovascular Disease Risk Assessment Guidelines
  The American Journal of Cardiology, 2008
• Enhanced Expression of Lp-PLA ₂ and Lysophosphatidylcholine in Symptomatic Carotid Atherosclerotic Plaques
  Stroke, 2008
• Associations of Plasma Fibrinogen Levels with Established Cardiovascular Disease Risk Factors, Inflammatory Markers, and Other Characteristics: Individual Participant Meta-Analysis of 154,211 Adults in 31 Prospective Studies: The Fibrinogen Studies Collaboration
  American Journal of Epidemiology, 2007
• Association Between Lipoprotein-Associated Phospholipase A2 and Cardiovascular Disease: A Systematic Review
  Mayo Clinic Proceedings, 2007
• Quantifying heterogeneity in a meta‐analysis
  Statistics in Medicine, 2002